Navigation Links
Three-Year Clinical Outcomes from Use of Genous™ Stent in Large, Real-World Patient Population Demonstrate Long-Term Safety and Efficacy
Date:11/8/2011

SAN FRANCISCO, Nov. 8, 2011 /PRNewswire/ -- OrbusNeich today announced that three-year clinical outcomes data from the use of the Genous Stent in a large, real-world patient population demonstrate the device's long-term safety and efficacy. These results were published in the October issue of the Journal of Interventional Cardiology.

At three-year clinical follow-up, the study's primary endpoint, a composite of cardiac death, myocardial infarction (MI) and target lesion revascularization (TLR), in an unselected patient population was 18.3%. Between one and three years, TLR had increased by only 3.6%, and no cases of late and very late definite stent thrombosis (ST) were observed.

"This is the first report of three-year clinical outcomes for the Genous Stent, and it is important to recognize that only a small number of studies have ever reported on three-year outcomes following percutaneous coronary intervention with stent placement in an all-comer population," said Margo Klomp, M.D., of the Academic Medical Center, Amsterdam, and lead author of the publication. "The target lesion failure rate of 18.3% in this case is on the lower end of the spectrum versus reported DES outcomes. In addition, late and very late ST was absent in our Genous Stent treated cohort, whereas other registries have reported occurrence of late and very late ST in DES treated patients."

The single-center study included 405 unselected patients with mostly complex lesions with an estimated high risk of restenosis. Specifically, 47% of the patients had multivessel disease, and, of the lesions treated, 75% were type B2/C lesions, 20% were chronic total occlusion (CTO) lesions, and 24% were bifurcated lesions. The average stent length was 24.6 +/- 11.7 mm. Patients were treated with clopidogrel for one month, and 16 patients received clopidogrel for less than one month. The duration of
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
2. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
3. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
4. MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices
5. Bacterin International Secures Three-Year Agreement to Distribute Biologic Products to Broadlanes Network of Over 6,000 Medical Facilities
6. Comfort Medical Supply, LLC Ranks No. 461 on the 2010 Inc. 500 with Three-Year Sales Growth of 649%
7. Universal SmartComp Ranks No. 503 Overall and No. 35 in the Health Sector on the 2010 Inc. 5000 with Three-Year Sales Growth of 600%
8. Three-Year Follow-Up Data Confirm Safety and Survival Benefit in Chinese Liver Failure Patients Treated With ELAD® Bioartificial Liver
9. Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytrens Contracture in E-poster at ASSH Meeting
10. MAQUET Cardiovascular Awarded Three-Year Contract From Premier Healthcare Alliance for Intra-Aortic Balloon Pumps
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Eisai Limited is pleased ... of the first-of-its-kind comic book available in Canada ... been designed specifically to educate children and their parents about ... affecting more than 300,000 Canadians. Eisai is guided ... (hhc) , in which the patient is central – there ...
(Date:8/21/2014)... Aug. 21, 2014 /PRNewswire-iReach/ -- Inc. ... for the third straight year, No. 349 in ... exclusive ranking of the nation,s fastest-growing private companies. ... the most important segment of the economy—America,s independent ... Domino,s Pizza, LinkedIn, Zillow, and many other well-known ...
(Date:8/21/2014)... Aug. 21, 2014  Seventy-one percent of Americans believe the ... a serious public health and safety issue in ... survey released today by Repass & Partners, a ... "Americans understand the severity of the prescription medication abuse problem ... this very serious health situation facing our country," Rex ...
Breaking Medicine Technology:Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3
... thinking about cosmetic surgery, your first stop should be at ...   SculptMyDream.com is the first website to let individuals ... photography.  Not only will this help you "Sculpt YOUR dream", ... that dream into reality. (Photo:   http://photos.prnewswire.com/prnh/20110720/NY38494 ...
... 20, 2011 Landacorp , A Carewise Health ... solutions, today announced that its CareRadius Suite has been ... Coventry Health Care is a diversified national ... plans that serve more than five million members across ...
Cached Medicine Technology:See the Results of Your Breast Augmentation, Before Surgery 2Coventry Health Care Selects Landacorp's CareRadius Suite to Advance Collaborative Care 2
(Date:8/21/2014)... DoudouneCanadienneGoosePasCher.fr, one of the most popular suppliers ... its new selection of Trillium Parkas for 2014. Moreover, ... these fashionable and comfortable items are available at discounted ... last until September 01. , The CEO says ... Canada Goose Trillium Parkas for new and old ...
(Date:8/21/2014)... is an internationally well-known supplier and leader in the ... collection of elegant bamboo floorings . These new ... for high quality floorings for their own houses. Now, ... to 29 percent off). Before the end of August, ... The company’s bamboo flooring products are made using unique, ...
(Date:8/21/2014)... Mich. Using heart-lung support technology, the University of ... of kidneys, livers and pancreases available for transplant by ... the journal Transplantation and detail the impact ... Oxygenation, or ECMO, to improve the quality and viability ... "Organ transplant is limited by the number of donated ...
(Date:8/21/2014)... 2014 Improv performers from Fun House ... dementia at Silverado Turtle Creek memory care community in ... entertainers ranging from ages 10 to 16, delivers a ... 40-minute set. The troupe's philosophy is that improv is ... them to touch audiences regardless of their circumstance — ...
(Date:8/21/2014)... 21, 2014 (HealthDay News) -- Black mothers are less ... here,s one possible reason why: Hospitals in neighborhoods with ... those in areas with more white residents, a U.S. ... are much less common in medical centers where the ... U.S. Centers for Disease Control and Prevention reported Thursday. ...
Breaking Medicine News(10 mins):Health News:Fashionable And Comfortable Canada Goose Trillium Parkas For Sale At DoudouneCanadienneGoosePasCher.fr 2Health News:Buy Elegant Bamboo Floorings from Internationally Well-known Supplier BambooIndustry.com 2Health News:Extracorporeal support can significantly increase number of organs for transplant 2Health News:Unicorn Clearance Improv Troupe Brings Laughter to Residents with Dementia at Silverado Memory Care 2Health News:Racial Disparities in Breast-Feeding May Start With Hospitals, Study Suggests 2
... , , HATBORO, Pa., Aug. 13 InfoLogix, Inc. ... solutions for the healthcare and commercial industries, today announced financial results for ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090618/NE3513 5 LOGO ... , , David T. Gulian, president and chief ...
... , , , BRISTOL, ... KG ) today announced that the U.S. Food and Drug ... Extended Release Capsules for oral use, a long-acting Schedule II ... when a continuous, around-the-clock opioid analgesic is needed for an ...
... , , REDWOOD ... ) today reported financial results and corporate progress for its fiscal ... , "With a slower than expected rate of ... quarter we had to make difficult decisions to revise our direct ...
... , , IRVINE, Calif., ... of surgical products used in the treatment of patients suffering from ... June 30, 2009. , , Net revenues in ... the prior year second quarter net revenues of $4,119,000. The ...
... rise if organ comes from deceased man, study finds, , ... donated organ came from a deceased male face an increased ... Canadian researchers have found. , The risk is short-term, though, ... researchers said. Their study found that the risk goes ...
... Genetic mutation could explain why some function fine on six hours ... few can get by just fine on six hours of sleep, ... why. , The finding doesn,t appear likely to help people with ... people sleep as long as they do, said study co-author Ying-Hui ...
Cached Medicine News:Health News:InfoLogix Announces Second Quarter Financial Results 2Health News:InfoLogix Announces Second Quarter Financial Results 3Health News:InfoLogix Announces Second Quarter Financial Results 4Health News:InfoLogix Announces Second Quarter Financial Results 5Health News:InfoLogix Announces Second Quarter Financial Results 6Health News:InfoLogix Announces Second Quarter Financial Results 7Health News:InfoLogix Announces Second Quarter Financial Results 8Health News:Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain 2Health News:Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain 3Health News:Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain 4Health News:Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain 5Health News:Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain 6Health News:Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain 7Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 2Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 3Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 4Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 5Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 6Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 7Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 8Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 9Health News:Cardiogenesis Reports Second Quarter 2009 Results 2Health News:Cardiogenesis Reports Second Quarter 2009 Results 3Health News:Cardiogenesis Reports Second Quarter 2009 Results 4Health News:Cardiogenesis Reports Second Quarter 2009 Results 5Health News:Cardiogenesis Reports Second Quarter 2009 Results 6Health News:Cardiogenesis Reports Second Quarter 2009 Results 7Health News:Kidney Donor's Sex Could Affect Women's Outcomes 2Health News:They Snooze Less, But They Don't Lose 2
High intensity halogen lamp with built-in, switchable spare. Optical light concentrator to optimize existing light energy....
... AlphaCor is a biocompatible, flexible, one-piece artificial ... or diseased native cornea., ,The World Health ... more than 10 million people worldwide, however ... year. This shortfall is due to a ...
PDA-version of the complete ICD-9 diagnosis codes....
PDA formatted guide containing outlines and detailed information on the diagnosis and treatment of HIV infection and AIDS....
Medicine Products: